Published on 10 Apr 2024 on GuruFocus.com via Yahoo Finance
Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024
Revenue: $16.6 million, up from $12.7 million in the same quarter last year, surpassing analyst estimates of $17.2288 million.Net Loss: $41.5 million, or ($0.76) per share, slightly missing analyst estimates of a net loss of $46.6215 million and an EPS of -$0.831.Research and Development Expenses: Increased to $50.0 million from $45.8 million year-over-year.General and Administrative Expenses: Rose to $11.8 million from $9.8 million in the previous year.Cash Position: $254.3 million in cash, cash equivalents, and marketable securities as of February 29, 2024.
Warning! GuruFocus has detected 7 Warning Signs with NRIX.
